Browse News
Filter News
Found 347 articles
-
Theralase(R) Release's 4Q2023 Interim Financial Statements
3/27/2024
Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's audited annual consolidated 2023 financial statements.
-
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
2/12/2024
Theralase Technologies Inc. donated two Theralase® TLC-2400 Cool Laser Therapy ("CLT") systems to the University of Windsor to aid in the research and development of a novel treatment for patients suffering from Parkinson's Disease ("Parkinson's").
-
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
1/15/2024
Theralase Technologies Inc. is providing an update regarding its Phase II Non-Muscle Invasive Bladder Cancer (" NMIBC ") clinical study (" Study II ").
-
TLC to Present at the 42nd Annual JP Morgan Healthcare Conference
12/27/2023
TLC BioSciences announced that the company will present at the 42nd Annual JP Morgan Healthcare Conference at 2:00pm PT on Tuesday, January 9, 2024.
-
Life Science Instrumentation Market Size To Hit USD 112.96 Billion By 2032
12/19/2023
Latest Study on “Life Science Instrumentation Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2023-2032”.
-
Theralase Release’s 3Q2023 Interim Financial Statements
11/29/2023
Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's 3Q2023 unaudited condensed interim consolidated Financial Statements.
-
Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session
11/20/2023
Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology Annual Meeting last week.
-
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR
11/8/2023
TLC BioSciences announced that the Abstract Selection Committee of the American College of Rheumatology has accepted TLC's late-breaking abstract on TLC599 for oral presentation at ACR Convergence 2023.
-
OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders
11/7/2023
OrsoBio, Inc. today announced the successful completion of a $60 million Series A financing, bringing the total capital raised by the Company to $97 million.
-
OrsoBio to Present Phase 1 Data for the Liver-Targeted Mitochondrial Protonophore TLC-6740 in Development for the Treatment of Obesity at ObesityWeek® 2023
10/16/2023
OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced preliminary safety and pharmacokinetic (PK) data from the single ascending dose (SAD) portion of an ongoing Phase 1 trial of TLC-6740, a liver-targeted, mitochondrial protonophore.
-
Theralase(R) Provides Update on Bladder Cancer Clinical Study
10/16/2023
Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical-stage pharmaceutical company dedicated to the research and development of light or radiation activated Photo Dynamic Compounds ("PDCs") for the safe and effective destruction of various cancers, bacteria and viruses.
-
SGD Pharma continues to innovate with the extension of its Ready-To-Use Sterinity glass vials for parenteral pharmaceutical applications, adding 10ml and 20ml to its ISO portfolio
10/12/2023
Global market leader in molded glass packaging solutions for the pharmaceutical industry, SGD Pharma announces the latest expansion of its Sterinity range of Ready-To-Use (RTU) Type I molded glass vials.
-
Theralase Release’s 2Q2023 Interim Financial Statements
8/29/2023
Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds, their associated drug formulations and the light systems that activate them, intended to safely and effectively destroy various cancers has released the Company's 2Q2023 unaudited condensed interim consolidated Financial Statements.
-
Theralase(R) Announces Appointment of New Independent Director
6/6/2023
Theralase Technologies Inc. is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc.
-
OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore for the Treatment of Obesity and Associated Diseases
6/5/2023
OrsoBio, Inc. today announced completion of the second cohort of subjects in an ongoing Phase 1 trial of TLC-6740, a liver-targeted mitochondrial protonophore.
-
Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
5/30/2023
Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company's 1Q2023 unaudited condensed interim consolidated Financial Statements.
-
Theralase(R) Releases 1Q2023 Interim Financial Statements
5/30/2023
Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company's 1Q2023 unaudited condensed interim consolidated Financial Statements.
-
Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer
5/24/2023
Theralase® Technologies Inc. is pleased to announce that Roger DuMoulin-White, B.Sc., P.Eng., Pro. Dir. has been appointed as President and Chief Executive Officer of the Company.
-
Theralase Provides Update on Phase II Bladder Cancer Study
5/10/2023
Theralase Technologies Inc. announced today an update on its recently reported Phase II clinical study ("Study II") interim clinical data.
-
Theralase® Releases FY2022 Audited Financial Statements
4/26/2023
Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers released its audited annual consolidated 2022 financial statements.